Three Cases of Advanced Melanoma With Severe irAE Colitis With Rapid Tumor Progression Following Infliximab Administration

Immune checkpoint inhibitors (ICIs) have improved melanoma outcomes but can cause severe immune-related colitis. Infliximab is often used for steroid-refractory cases, yet its effect on tumor control remains uncertain. We describe three advanced melanoma patients who developed grade 3-4 colitis after nivolumab plus ipilimumab and were treated with infliximab. Although gastrointestinal symptoms improved, all showed rapid disease progression and died within 3-9 months. These cases suggest that infliximab may compromise antitumor immunity in melanoma patients receiving ICIs.